Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Indivior : Says Reckitt Benckiser's Claim is Without Merit

11/30/2020 | 02:55am EST

By Adria Calatayud

Indivior PLC said Monday that it believes a claimed filed by Reckitt Benckiser Group PLC against it is without merit and vowed to fully and vigorously defend itself in any proceedings related to the claim.

The U.K. pharmaceutical company on Friday said a claim for 1.07 billion pounds ($1.42 billion) against it had been submitted to the Commercial Court in London by consumer-goods giant Reckitt Benckiser on Nov. 13. Indivior said the claim relates to an indemnity contained in a 2014 demerger agreement between it and Reckitt Benckiser.

The claim hasn't been served on Indivior at the present time, the company said.

Indivior noted comments by Reckitt Benckiser in The Times of London and Financial Times newspapers that it "regularly takes certain procedural steps to preserve potential claims."

Indivior said it believes it has strong grounds for defending against the claim should it be served, based on the information available to the company.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

11-30-20 0254ET

Stocks mentioned in the article
ChangeLast1st jan.
INDIVIOR -1.66% 130.3 Delayed Quote.19.85%
RECKITT BENCKISER GROUP PLC 0.22% 6274 Delayed Quote.-4.10%
All news about INDIVIOR
01/15INDIVIOR : The Department of Health and Human Services Announces New Guidance In..
PU
01/15LONDON STOCK EXCHANGE : FTSE 100 logs worst week since October-end on lockdown w..
RE
01/15INDIVIOR : Provides Preliminary FY 2020 Financial Results Ahead of Guidance
PU
01/15INDIVIOR : raises revenue forecast as U.S. opioid treatment sales recover
RE
01/15INDIVIOR : Lifts Net Revenue Guidance for 2020, Flags Higher-than-Expected Adjus..
MT
01/12INDIVIOR : Directorate Change
PU
01/12PRESS RELEASE : Addex to Present at the Baader Helvea Swiss Equities Conference
DJ
01/11PRESS RELEASE : Addex Successfully Completes $11.5 Million Capital Increase Incl..
DJ
2020INDIVIOR : Claim filed by Reckitt Benckiser Group
PU
2020PRESS RELEASE : Addex Announces Filing of Registration Statement for Proposed Pu..
DJ
More news
Financials (USD)
Sales 2020 648 M - -
Net income 2020 -104 M - -
Net cash 2020 612 M - -
P/E ratio 2020 -10,6x
Yield 2020 -
Capitalization 1 309 M 1 307 M -
EV / Sales 2020 1,08x
EV / Sales 2021 1,13x
Nbr of Employees 796
Free-Float 98,5%
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 2,88 $
Last Close Price 1,78 $
Spread / Highest target 146%
Spread / Average Target 61,7%
Spread / Lowest Target 19,3%
EPS Revisions
Managers and Directors
NameTitle
Mark Crossley Executive Director, CEO & COO
Graham C. Hetherington Chairman
Ryan Preblick Chief Financial Officer & Executive Director
Christian Heidbreder Chief Scientific Officer
A. Thomas McLellan Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR19.85%1 307
MERCK KGAA0.53%74 677
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD11.98%27 883
KYOWA KIRIN CO., LTD.-1.28%14 378
BETTA PHARMACEUTICALS CO., LTD.33.28%8 898
YUHAN CORPORATION-3.60%4 265